Combination Therapy and Payer Perspective on CKD Therapies

September 28, 2022 03:35pm

Dr Bertram Pitt explains the possibility of combining SGLT2 inhibitors and MRAs when treating CKD and CV, and Paul Sapia, MHA, discusses how payers balance cost of care with disease progression and health disparities.

Potential for PHC Necessitates Pediatric Cardiology Care for Children With PAH
Using Published Data to Consider SGLT2 Inhibitors and MRAs in CKD Management
Alzheimer Disease Drug Lecanemab Successfully Reduces Cognitive, Functional Decline
Utilizing Pirfenidone in ILD Treatment Strategy